IGF2BP3 has been characterized as an oncoprotein and a useful biomarker for a variety of cancers, including adenocarcinoma (34), intrahepatic cholangiocarcinoma (35), squamous esophageal cancer (36), and colon cancer (37). This evidence concerns the gene IGF2BP3 and intrahepatic cholangiocarcinoma.